BB Biotech

BB Biotech AG is one of the world’s largest and oldest dedicated biotech investors. It focuses on investing in innovative biotechnology firms—primarily small-to-mid-cap public and private companies—developing or commercializing novel drugs that address significant unmet medical needs. Its core holdings are typically late-stage or commercial-stage biotechs with strong growth potential. The firm’s strategy emphasizes oncology, rare/orphan diseases, neurology/CNS disorders as well as emerging technologies such as RNA-based therapies and cell/gene therapies. The current core holdings include Argenx, Ionis Pharmaceuticals, Neurocrine Biosciences, Intra‑Cellular Therapies, Revolution Medicines, Vertex Pharmaceuticals, Alnylam Pharmaceuticals and Incyte.